Bevacizumab maintenance (post 1L platinum, ovarian/fallopian/primary peritoneal)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-BEVACIZUMAB`

ID	`REG-BEV-MAINTENANCE-OVARIAN`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

GOG-218 (Burger 2011, NEJM) and ICON7 (Perren 2011, NEJM) established bevacizumab maintenance after 6 cycles carboplatin-paclitaxel ± concurrent bevacizumab. Highest absolute benefit in stage III suboptimally debulked or stage IV. Often combined with PARP maintenance (PAOLA-1: bev + olaparib) in HRD-positive disease; see REG-OLAPARIB-MAINTENANCE-OVARIAN. Avoid in patients with bowel-wall invasion or recent bowel surgery (perforation risk).

Used By

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning

Indication

IND-OVARIAN-MAINT-BEV - IND-OVARIAN-MAINT-BEV